Literature DB >> 7769310

Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus.

J L Mainardi1, D M Shlaes, R V Goering, J H Shlaes, J F Acar, F W Goldstein.   

Abstract

Between February 1992 and February 1993, 12 patients were seen who were infected or colonized with methicillin-resistant strains of Staphylococcus aureus. The strains had decreased susceptibility to teicoplanin (MICs, 8-16 micrograms/mL). Field inversion gel electrophoresis showed the strains belonged to three related clones (A1, A2, and A3). The patients were though to have acquired the strains nosocomially. Consistent with results of laboratory studies of teicoplanin-resistant S. aureus, all but 1 strain expressed a 35-kDa membrane protein, and 9 strains expressed increased levels of penicillin-binding protein 2 complex. Six strains were isolated from patients treated with glycopeptides. These data suggest that nosocomial transmission of S. aureus with decreased teicoplanin susceptibility may occur during glycopeptide use and that such strains develop resistance by a mechanism associated with the appearance of a 35-kDa membrane protein. Surveillance is necessary to monitor for the potential selection of resistant clones that may be capable of dissemination.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7769310     DOI: 10.1093/infdis/171.6.1646

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital.

Authors:  A Marchese; G Balistreri; E Tonoli; E A Debbia; G C Schito
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates.

Authors:  S Boyle-Vavra; S K Berke; J C Lee; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

3.  Transcriptional induction of the penicillin-binding protein 2 gene in Staphylococcus aureus by cell wall-active antibiotics oxacillin and vancomycin.

Authors:  Susan Boyle-Vavra; Shaohui Yin; Mamatha Challapalli; Robert S Daum
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

4.  In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae.

Authors:  M D Kitzis; A Ly; F W Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

5.  Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus.

Authors:  B Moreira; S Boyle-Vavra; B L deJonge; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 6.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

7.  Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin.

Authors:  M W Climo; R L Patron; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

8.  Jacques F. Acar (1931-2020).

Authors:  E Cambau; L Gutmann; J-L Mainardi; F Goldstein; A Buu-Hoi; E Collatz; M Poljak; G Kahlmeter; I Phillips; F Baquero
Journal:  Clin Microbiol Infect       Date:  2020-06-11       Impact factor: 8.067

9.  Overproduction of a 37-kilodalton cytoplasmic protein homologous to NAD+-linked D-lactate dehydrogenase associated with vancomycin resistance in Staphylococcus aureus.

Authors:  W M Milewski; S Boyle-Vavra; B Moreira; C C Ebert; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

Review 10.  Novel anti-infective compounds from marine bacteria.

Authors:  Hafizur Rahman; Brian Austin; Wilfrid J Mitchell; Peter C Morris; Derek J Jamieson; David R Adams; Andrew Mearns Spragg; Michael Schweizer
Journal:  Mar Drugs       Date:  2010-03-05       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.